IS ABBVIE INC. (ABBV) THE BEST PHARMA STOCK TO BUY FOR LONG TERM GROWTH?
https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee
✍️ The article discusses the trend of US pharmaceutical companies acquiring Chinese pharmaceutical firms for their sophisticated development skills and ability to produce potent compounds at a lower cost.
👉 US pharmaceutical companies are acquiring Chinese pharmaceutical firms for their sophisticated development skills and ability to produce potent compounds at a lower cost. 👉 30% of big pharma acquisitions in 2024 involved Chinese corporations. 👉 Chinese companies can produce potent compounds in large quantities and charge a lower price. 👉 Chinese companies have a more streamlined development process, allowing them to start testing on human subjects more quickly. 👉 AbbVie Inc. (NYSE:ABBV) is one of the best pharma stocks to buy for long-term growth, with a 5-year revenue growth of 10% and a strong dividend growth pattern.
-- #TimOpler #EmilyField #China #US #business
Loading quoted post…
